Intel stock spikes after report of possible US government stake
Investing.com - H.C. Wainwright downgraded Karyopharm Therapeutics (NASDAQ:KPTI) from Buy to Neutral on Wednesday, removing its price target following the company’s announcement of workforce reductions and financial challenges. According to InvestingPro data, the company’s stock has declined over 71% in the past year, with a market capitalization now standing at just $36.6 million.
The pharmaceutical company revealed late last week that it would cut approximately 20% of its workforce after confidential discussions with potential investors failed to secure additional financing. As of the end of the first quarter of 2025, Karyopharm reported $70.3 million in cash and cash equivalents on its balance sheet. InvestingPro analysis shows the company carries a significant debt burden of $260.2 million and is rapidly burning through cash, with negative free cash flow of $122.7 million in the last twelve months.
According to H.C. Wainwright, this cash position should provide Karyopharm with an operational runway into the first quarter of 2026. The company is now evaluating strategic alternatives to maximize shareholder value, which may include a potential merger or sale.
The downgrade also takes into account that top-line results from Karyopharm’s Phase 3 trial evaluating selinexor in JAKi-naive myelofibrosis are not expected until the first quarter of 2026.
H.C. Wainwright removed its previous price target for Karyopharm stock as part of the downgrade to Neutral from Buy.
In other recent news, Karyopharm Therapeutics reported a mixed financial performance for the first quarter of 2025, with revenue reaching $30 million, falling short of the forecasted $37.84 million. The company also faced challenges with its SENTRY Phase III study for myelofibrosis, as slower enrollment rates have delayed data availability. In an attempt to manage operating expenses, Karyopharm announced a workforce reduction of approximately 20%. The company is exploring strategic alternatives, including potential mergers or sales, after unsuccessful financing talks. RBC Capital Markets adjusted its outlook on Karyopharm, reducing the price target from $34.00 to $33.00, while maintaining an Outperform rating. Karyopharm also announced an amendment to its 2022 Equity Incentive Plan, increasing the share reserve by 450,000 shares, approved at the Annual Meeting. The company’s revenue guidance for 2025 is set between $140 million and $155 million, with U.S. Xpovio net product revenue expected to range from $115 million to $130 million. The company remains committed to advancing its Phase III clinical trials in myelofibrosis and endometrial cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.